Actively Recruiting
Evaluating Osimertinib With or Without Stereotactic Radiosurgery SRS for Brain Metastases in Non-Small Cell Lung Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-10-28
56
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether adding stereotactic radiosurgery SRS after three months of treatment with osimertinib improves outcomes compared to osimertinib alone in people with non-small cell lung cancer NSCLC that has spread to the brain. This study also evaluates how these approaches affect participants quality of life through questionnaires. Both study arms receive standard systemic therapy with osimertinib, an FDA-approved drug targeting mutant EGFR in the brain. Participants are randomly assigned to receive either osimertinib combined with SRS or osimertinib alone. SRS dosing varies by size of brain metastases, with different radiation doses and schedules depending on lesion size. The study is a phase 2 trial with parallel groups comparing these treatments. The treatment period follows initial three months of osimertinib therapy, after which participants are evaluated and randomized based on brain metastases status. During the study, participants complete quality of life questionnaires and undergo brain MRI scans with contrast to assess tumor status and progression. The main outcome measured is intracranial progression-free survival at three months, with additional monitoring of time to central nervous system progression at nine months. The study involves regular imaging and clinical evaluations to track treatment effects and safety until the studys completion in December 2027.
CONDITIONS
Brief Title
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
Research Team
L
Luke Pike, MD
H
Helena Yu, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here